@article {7090,
	title = {Carfilozomib versus bortezomib for relapsed or refractory myeloma {\textendash} Authors{\textquoteright} reply},
	journal = {The Lancet Oncology},
	volume = {17},
	year = {2016},
	note = {Export Date: 18 February 2017References: Dimopoulos, M.A., Moreau, P., Palumbo, A., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study (2016) Lancet Oncol, 17, pp. 27-38;Durie, B.G., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; 
Rajkumar, S.V., Harousseau, J.L., Durie, B., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 (2011) Blood, 117, pp. 4691-4695
},
	month = {2016},
	pages = {e126},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977540032\&doi=10.1016\%2fS1470-2045\%2816\%2900145-5\&partnerID=40\&md5=40c687754e19de4d23dabfa69079747a},
	author = {Dimopoulos, M.A. and Moreau, P. and Palumbo, A. and Chng, W.-J. and Feng, S.}
}
